EVOQ Bio

About the offering

EVOQ Bio is a pre-clinical drug development company headquartered in Salt Lake City, Utah, focused on engineering EVQ-218, a novel inhaled antimicrobial candidate designed to treat multidrug-resistant lung infections. The company's platform uses a physical, nanoscale architecture (described as a 'metamaterial' approach) rather than traditional chemical binding mechanisms, with the goal of circumventing the resistance pathways that limit conventional antibiotics. Key scientific and regulatory milestones include: (1) Peer-reviewed publication in ACS Omega characterizing the nanoscale architecture of the platform; (2) Peer-reviewed publication in Antibiotics demonstrating broad-spectrum antimicrobial activity and no observed resistance development over 30 serial passages, while standard-of-care antibiotics tobramycin and ciprofloxacin showed diminished effectiveness under the same conditions; (3) Studies conducted at Seattle Children's Research Institute showing bactericidal activity against 64 diverse clinical isolates, including multidrug-resistant ESKAPE pathogens; (4) Inhalation toxicology studies in rats at Lovelace Biomedical showing favorable tolerability; and (5) A completed Pre-IND meeting with the FDA providing regulatory guidance toward an Investigational New Drug (IND) application and first-in-human trials. The company has received $498,000 in non-dilutive awards from the Cystic Fibrosis Foundation. The initial commercial target is the cystic fibrosis patient population, where chronic pulmonary bacterial infections are a leading cause of morbidity and mortality, with potential expansion to pneumococcal pneumonia, COPD-related infections, and immunocompromised oncology patients. EVOQ Bio holds exclusive worldwide license rights for certain therapeutic applications of the technology, along with nonexclusive rights to related manufacturing patents. The leadership team includes CEO Shaun Rothwell (entrepreneur and business leader), Chief Development Officer David Nilson (20+ years in biotech/pharma/genomics), and General Counsel and Board Member David Parkinson (attorney since 1998 with a public health and cystic fibrosis advocacy background). Tony Robbins is noted as a paid advisor and equity investor in the parent entity EVOQ Nano, Inc. Proceeds from this offering are intended to fund IND-enabling studies required to initiate clinical trials. EVQ-218 has not been approved by the FDA, and all efficacy and safety data referenced are from preclinical studies.

FAQ